Literature DB >> 18424902

Creutzfeldt-Jakob disease in Austria: an autopsy-controlled study.

Ellen Gelpi1, Harald Heinzl, Romana Hoftberger, Ursula Unterberger, Thomas Strobel, Till Voigtlander, Edita Drobna, Christa Jarius, Susanna Lang, Thomas Waldhor, Hanno Bernheimer, Herbert Budka.   

Abstract

BACKGROUND: Definite diagnosis of prion diseases or transmissible spongiform encephalopathies (TSEs) requires neuropathology, usually at autopsy. Epidemiology of human TSEs has relied on definite as well as 'probable' cases in which neuropathological confirmation is lacking, usually because of low autopsy rates in most countries.
METHODS: In Austria, an active surveillance program for human prion diseases was established in 1996. Since then, more than 900 referrals were analyzed. Postmortem investigation of brain tissue is mandatory in every suspect case of TSE. Thus, epidemiological data on TSEs from Austria may serve as autopsy-controlled reference for countries with lower autopsy rates.
RESULTS: The total number of TSE cases in Austria since 1969 is 206. The average yearly mortality for the active surveillance period from 1996 to 30 June 2006 is 1.39 per million, with the highest rates for Vienna (2.37) compared with other provinces. Eighty-five percent of definite TSEs were classified as sporadic Creutzfeldt-Jakob disease (sCJD). We observed a significant linear increase in the mean age at death of 0.6 years per calendar year. Clinical diagnostic surveillance criteria had a sensitivity and specificity of 82.7 and 80.0% for probable CJD, respectively, and a positive predictive value of 80.5% for probable and 38.9% for 'possible' CJD. Alternative neuropathological diagnoses in suspect cases included Alzheimer's disease with or without Lewy body pathology, vascular encephalopathy, metabolic encephalopathies and viral or limbic encephalitis.
CONCLUSION: The steady increase in mortality rates, especially in old age groups, most likely reflects improved case ascertainment due to active surveillance causing higher awareness of the medical community. In comparison with other European countries, it is reassuring to note that the overall death rate of TSEs does not differ from the Austrian autopsy-controlled data, thus confirming the value of clinical surveillance criteria. Copyright 2008 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2008        PMID: 18424902     DOI: 10.1159/000126915

Source DB:  PubMed          Journal:  Neuroepidemiology        ISSN: 0251-5350            Impact factor:   3.282


  10 in total

1.  Induction of pluripotent stem cells from autopsy donor-derived somatic cells.

Authors:  Brooke E Hjelm; Jon B Rosenberg; Szabolcs Szelinger; Lucia I Sue; Thomas G Beach; Matthew J Huentelman; David W Craig
Journal:  Neurosci Lett       Date:  2011-08-04       Impact factor: 3.046

2.  Incidence of Creutzfeldt-Jakob disease in Taiwan: a prospective 10-year surveillance.

Authors:  Chien-Jung Lu; Yu Sun; Shun-Sheng Chen
Journal:  Eur J Epidemiol       Date:  2010-03-24       Impact factor: 8.082

3.  Pellagra encephalopathy as a differential diagnosis for Creutzfeldt-Jakob disease.

Authors:  Istvan Kapas; Katalin Majtenyi; Klara Törö; Eva Keller; Till Voigtländer; Gabor G Kovacs
Journal:  Metab Brain Dis       Date:  2012-04-27       Impact factor: 3.584

4.  Treatable neurological disorders misdiagnosed as Creutzfeldt-Jakob disease.

Authors:  Numthip Chitravas; Richard S Jung; Diane M Kofskey; Janis E Blevins; Pierluigi Gambetti; R John Leigh; Mark L Cohen
Journal:  Ann Neurol       Date:  2011-06-14       Impact factor: 10.422

5.  Serum tau protein as a marker for the diagnosis of Creutzfeldt-Jakob disease.

Authors:  Moeko Noguchi-Shinohara; Tsuyoshi Hamaguchi; Ichiro Nozaki; Kenji Sakai; Masahito Yamada
Journal:  J Neurol       Date:  2011-03-01       Impact factor: 4.849

Review 6.  Rapidly progressive dementias - aetiologies, diagnosis and management.

Authors:  Peter Hermann; Inga Zerr
Journal:  Nat Rev Neurol       Date:  2022-05-04       Impact factor: 44.711

7.  Racial and ethnic differences in individuals with sporadic Creutzfeldt-jakob disease in the United States of America.

Authors:  Brian S Appleby; Tonya D Rincon-Beardsley; Kristin K Appleby; Mitchell T Wallin
Journal:  PLoS One       Date:  2012-06-18       Impact factor: 3.240

8.  Duration of prion disease is longer in Japan than in other countries.

Authors:  Kiwamu Nagoshi; Atsuko Sadakane; Yosikazu Nakamura; Masahito Yamada; Hidehiro Mizusawa
Journal:  J Epidemiol       Date:  2011-05-28       Impact factor: 3.211

9.  Accuracy of diagnosis criteria in patients with suspected diagnosis of sporadic Creutzfeldt-Jakob disease and detection of 14-3-3 protein, France, 1992 to 2009.

Authors:  Laurene Peckeu; Nicole Delasnerie-Lauprètre; Jean-Philippe Brandel; Dominique Salomon; Véronique Sazdovitch; Jean-Louis Laplanche; Charles Duyckaerts; Danielle Seilhean; Stéphane Haïk; Jean-Jacques Hauw
Journal:  Euro Surveill       Date:  2017-10

10.  Analysis of Chinese patients with sporadic Creutzfeldt-Jakob disease.

Authors:  Jing Yang; Haiyan Kuang; Qiong Wang; Jiao Liu; Xueping Chen; Huifang Shang
Journal:  Prion       Date:  2020-12       Impact factor: 3.931

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.